Li Ou

Dr. Li Ou

Shaanxi University of Chinese Medicine
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Acta Cirurgica Brasileira
Verified
Journal Article
Open access
PDF file
LOLi Ou
Li Ou
PWPeifeng Wei
Peifeng Wei
MLMin Li
Min Li
FGFeng Gao
Feng Gao
Key words: Astragalus Plant; Osteoporosis; Ovariectomy; Rats

1 January 2021 in Acta Cirurgica Brasileira
Verified
Journal Article
Open access
PDF file
LOLi Ou
Li Ou
WKWenqian Kang
Wenqian Kang
JZJiahao Zhang
Jiahao Zhang
ZLZiyi Liang
Ziyi Liang
MLMin Li
Min Li
LCLin Chen
Lin Chen
To study effects of Rehmannia glutinosa polysaccharides (RGP) on bone tissue structure and skeletal muscle atrophy in rats with disuse. A rat model of disuse osteoporosis combined with muscle atrophy was established by removing the bilateral ovaries of rats and fixing their hind limbs for a long time. Forty SD rats were administered intragastrically for 12 weeks. The bone histomorphometry parameters and the level of oxidative stress were measured. In addition, the changes of muscle atrophy F-box (MAFbx), muscle RING-finger protein-1 (MuRF1), forkhead box O1 (FOXO1) mRNA expression in skeletal muscle of rats were observed. RGP significantly increased the percentage of fluorescence perimeter and bone mineralization deposition rate of the second lumbar vertebrae of rats. It also significantly increased the wet weight ratio and muscle fiber cross-sectional area of the gastrocnemius muscle of rats. At the same time, RGP significantly increased the levels of super oxide dismutase (SOD) and catalase (CAT) in the skeletal muscle of rats, and reduced the content of malondialdehyde (MDA). Rehmannia glutinosa polysaccharides also significantly reduced the expression levels of FOXO1, MAFbx and MuRF1 mRNA in rat skeletal muscle. RGP could improve the bone structure of osteoporotic rats. It could also improve muscle that atrophy may be related to the inhibition of FOXO1-mediated ubiquitin-proteasome pathway.

14 October 2021 in Journal of Orthopaedic Surgery and Research
Verified
Journal Article
Open access
PDF file
LOLi Ou
Li Ou
WKWenqian Kang
Wenqian Kang
ZLZiyi Liang
Ziyi Liang
FGFeng Gao
Feng Gao
TDTaiwei Dong
Taiwei Dong
MLMin Li
Min Li
Background: Rehmanniae Radix Preparata (RRP) can effectively improve the symptoms of osteoporosis, but its molecular mechanism for treating osteoporosis is still unclear. The objective of this study is to investigate the anti-osteoporosis mechanisms of RRP through network pharmacology. Methods: The overlapping targets of RRP and osteoporosis were screened out using online platforms. A visual network diagram of PPI was constructed and analyzed by Cytoscape 3.7.2 software. Molecular docking was used to evaluate the binding activity of ligands and receptors, and some key genes were verified through pharmacological experiments. Results: According to topological analysis results, AKT1, MAPK1, ESR1, and SRC are critical genes for RRP to treat osteoporosis, and they have high binding activity with stigmasterol and sitosterol. The main signal pathways of RRP in the treatment of osteoporosis, including the estrogen signaling pathway, HIF-1 signal pathway, MAPK signal pathway, PI3K-Akt signal pathway. Results of animal experiments showed that RRP could significantly increase the expression levels of Akt1, MAPK1, ESR1, and SRC1 mRNA in bone tissue to increase bone density. Conclusion: This study explained the coordination between multiple components and multiple targets of RRP in the treatment of osteoporosis and provided new ideas for its clinical application and experimental research.

17 July 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
QLQiao Liu
Qiao Liu
TDTaiwei Dong
Taiwei Dong
MXMiaomiao Xi
Miaomiao Xi
LGLicheng Gou
Licheng Gou
YBYang Bai
Yang Bai
PWPei-Feng Wei
Pei-Feng Wei
Introduction. Coronary heart disease (CHD) is a common clinical cardiovascular disease, and its morbidity and mortality rates are increasing, which brings a serious burden to the family and society. Dyslipidemia is one of the most important risk factors for CHD. However, it is difficult to reduce blood lipids to an ideal state with the administration of a statin alone. Tongxinluo capsule (TXLC), as a Chinese patent medicine, has received extensive attention in the treatment of CHD in recent years. This systematic review and meta-analysis aim to provide evidence-based medicine for TXLC combined with atorvastatin in the treatment of CHD. Objective. To evaluate systematically the effectiveness and safety of TXLC combined with atorvastatin in the treatment of CHD. Methods. Seven English and Chinese electronic databases (PubMed, Cochrane Library, Embase, CNKI, VIP, CBM, and Wanfang) were searched from inception to January 2020, to search for randomized controlled trials (RCTs) on TXLC combined with atorvastatin in the treatment of CHD. Two researchers independently screened the literature according to the literature inclusion and exclusion criteria and performed quality assessment and data extraction on the included RCTs. We performed a systematic review following Cochrane Collaboration Handbook and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and using a measurement tool to assess the methodological quality of systematic reviews (AMSTAR 2). The quality of outcomes was evaluated by the Grading of Recommendations Assessment, Development and Evaluation (GRADE). And meta-analysis was performed by Review Manager 5.2. Results. A total of 15 RCTs with 1,578 participants were included in this review. Compared to atorvastatin treatment, TXLC combined with atorvastatin treatment showed potent efficacy when it came to the effectiveness of clinical treatment (RR = 1.24; 95% CI, 1.18, 1.29; P < 0.00001 ), total cholesterol (TC; MD = −1.21; 95% CI, −1.53, −0.89; P < 0.00001 ), triacylglycerol (TG; MD = −0.73; 95% CI, −0.81, −0.65; P < 0.00001 ), high-density lipoprotein cholesterol (HDL-C; MD = 0.27; 95% CI, 0.23, 0.31; P < 0.00001 ), low-density lipoprotein cholesterol (LDL-C; MD = –0.72; 95% CI, –0.80, −0.64; P < 0.00001 ), C-reactive protein (CRP; SMD = −2.06; 95% CI, −2.56, −1.57; P < 0.00001 ), frequency of angina pectoris (SMD = −1.41; 95% CI, −1.97, −0.85; P < 0.00001 ), duration of angina pectoris (MD = −2.30; 95% CI, −3.39, −1.21; P < 0.0001 ), and adverse reactions (RR = 0.84; 95% CI, 0.51, 1.39; P = 0.50 ). No serious adverse events or reactions were mentioned in these RCTs. According to the PRISMA guidelines, although all studies were not fully reported in accordance with the checklist item, the reported items exceeded 80% of all items. With the AMSTAR 2 standard, the methodological quality assessment found that 9 studies were rated low quality and 6 studies were rated critically low quality. Based on the results of the systematic review, the GRADE system recommended ranking method was used to evaluate the quality of evidence and the recommendation level. The results showed that the level of evidence was low, and the recommendation intensity was a weak recommendation. Conclusions. TXLC combined with atorvastatin in the treatment of CHD can effectively improve the effectiveness of clinical treatment, significantly reduce the frequency and duration of angina pectoris, decrease blood lipids, and improve inflammatory factors. However, due to the low quality of the literature included in these studies and the variability of the evaluation methods of each study, there is still a need for a more high-quality, large sample, multicenter clinical randomized control for further demonstration.

1 January 2022 in Acta Cirurgica Brasileira
Verified
Journal Article
Open access
WKWen-Qian Kang
Wen-Qian Kang
PWPei-Feng Wei
Pei-Feng Wei
LOLi Ou
Li Ou
MLMin Li
Min Li
CLChun-Yu Liu
Chun-Yu Liu
To observe the mechanism of prepared Radix Rehmanniainon combined with Radix Astragali in treating osteoporosis. Osteoporosis rat model was established by bilateral ovariectomy combined with low-calcium diet feeding. Bone mineral density was measured by bone densitometer. Bone metabolism markers in serum were detected by enzyme linked immunosorbent assay (ELISA), bone tissue structure was observed by hematoxylin-eosin staining, and the effect of prepared Radix Rehmanniainon combined with Radix Astragali on PI3K-AKT signaling pathway was investigated by immunohistochemistry and reverse transcription polymerase chain reaction. Compared with the model group, the bone tissue structure and imbalance of bone metabolism were improved, and the bone mineral density was significantly increased in the prepared Radix Rehmanniainon combined with Radix Astragali groups. After intervention with prepared Radix Rehmanniainon combined with Radix Astragali, the positive expression of PIK3CA and Akt1 in rat bone tissue was enhanced, and the expression levels of Akt1 mRNA were significantly increased. Prepared Radix Rehmanniainon combined with Radix Astragali may treat osteoporosis by activating PI3K/AKT pathway.

1 January 2024 in The American Journal of Chinese Medicine
Verified
Journal Article
Closed access
MZMengmeng Zhang
Mengmeng Zhang
XWXu Wu
Xu Wu
HGHuanqing Gao
Huanqing Gao
LZLin Zhang
Lin Zhang
YLYao Li
Yao Li
LOLi Ou
Li Ou